Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Abdel-Maksoud, Mohammed S. | - |
dc.contributor.author | El-Gamal, Mohammed I. | - |
dc.contributor.author | Benhalilou, Dalia Reyane | - |
dc.contributor.author | Ashraf, Sandy | - |
dc.contributor.author | Mohammed, Shatha Abdulghaffar | - |
dc.contributor.author | Oh, Chang-Hyun | - |
dc.date.accessioned | 2024-01-19T20:33:42Z | - |
dc.date.available | 2024-01-19T20:33:42Z | - |
dc.date.created | 2021-09-02 | - |
dc.date.issued | 2019-03 | - |
dc.identifier.issn | 0198-6325 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/120307 | - |
dc.description.abstract | The mechanistic/mammalian target of rapamycin (mTOR), also known as the mechanistic target of rapamycin, regulates many normal cell processes such as transcription, cell growth, and autophagy. Overstimulation of mTOR by its ligands, amino acids, sugars, and/or growth factors leads to physiological disorders, including cancer and neurodegenerative diseases. In this study, we reviewed the recent advances regarding the mechanism that involves mTOR in cancer, aging, and neurodegenerative diseases. The chemical and biological properties of recently reported small molecules that function as mTOR kinase inhibitors, including adenosine triphosphate-competitive inhibitors and dual mTOR/PI3K inhibitors, have also been reviewed. We focused on the reports published in the literature from 2012 to 2017. | - |
dc.language | English | - |
dc.publisher | WILEY | - |
dc.subject | ORALLY BIOAVAILABLE INHIBITORS | - |
dc.subject | LIFE-SPAN EXTENSION | - |
dc.subject | MAMMALIAN TARGET | - |
dc.subject | BIOLOGICAL EVALUATION | - |
dc.subject | AMINO-ACID | - |
dc.subject | IN-VITRO | - |
dc.subject | PYRIMIDINE-DERIVATIVES | - |
dc.subject | ANTITUMOR-ACTIVITY | - |
dc.subject | SIGNALING PATHWAY | - |
dc.subject | KINASE INHIBITOR | - |
dc.title | Mechanistic/mammalian target of rapamycin: Recent pathological aspects and inhibitors | - |
dc.type | Article | - |
dc.identifier.doi | 10.1002/med.21535 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | MEDICINAL RESEARCH REVIEWS, v.39, no.2, pp.631 - 664 | - |
dc.citation.title | MEDICINAL RESEARCH REVIEWS | - |
dc.citation.volume | 39 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 631 | - |
dc.citation.endPage | 664 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000458338000007 | - |
dc.identifier.scopusid | 2-s2.0-85054011986 | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Review | - |
dc.subject.keywordPlus | ORALLY BIOAVAILABLE INHIBITORS | - |
dc.subject.keywordPlus | LIFE-SPAN EXTENSION | - |
dc.subject.keywordPlus | MAMMALIAN TARGET | - |
dc.subject.keywordPlus | BIOLOGICAL EVALUATION | - |
dc.subject.keywordPlus | AMINO-ACID | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | PYRIMIDINE-DERIVATIVES | - |
dc.subject.keywordPlus | ANTITUMOR-ACTIVITY | - |
dc.subject.keywordPlus | SIGNALING PATHWAY | - |
dc.subject.keywordPlus | KINASE INHIBITOR | - |
dc.subject.keywordAuthor | aging | - |
dc.subject.keywordAuthor | anticancer | - |
dc.subject.keywordAuthor | kinase inhibitors | - |
dc.subject.keywordAuthor | mTOR | - |
dc.subject.keywordAuthor | PI3K | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.